Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

Harold E Bays, Eliot A Brinton, Joseph Triscari, Erluo Chen, Darbie Maccubbin, Alexandra A MacLean, Kendra L Gibson, Rae Ann Ruck, Amy O Johnson-Levonas, Edward A O'Neill, Yale B Mitchel, Harold E Bays, Eliot A Brinton, Joseph Triscari, Erluo Chen, Darbie Maccubbin, Alexandra A MacLean, Kendra L Gibson, Rae Ann Ruck, Amy O Johnson-Levonas, Edward A O'Neill, Yale B Mitchel

Abstract

Background: The degree of glycemic control in patients with type 2 diabetes mellitus (T2DM) may alter lipid levels and may alter the efficacy of lipid-modifying agents.

Objective: Evaluate the lipid-modifying efficacy of extended-release niacin/laropiprant (ERN/LRPT) in subgroups of patients with T2DM with better or poorer glycemic control.

Methods: Post hoc analysis of clinical trial data from patients with T2DM who were randomized 4:3 to double-blind ERN/LRPT or placebo (n=796), examining the lipid-modifying effects of ERN/LRPT in patients with glycosylated hemoglobin or fasting plasma glucose levels above and below median baseline levels.

Results: At Week 12 of treatment, ERN/LRPT significantly improved low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol, triglycerides, and lipoprotein (a), compared with placebo, with equal efficacy in patients above or below median baseline glycemic control. Compared with placebo, over 36 weeks of treatment more patients treated with ERN/LRPT had worsening of their diabetes and required intensification of antihyperglycemic medication, irrespective of baseline glycemic control. Incidences of other adverse experiences were generally low in all treatment groups.

Conclusion: The lipid-modifying effects of ERN/LRPT are independent of the degree of baseline glycemic control in patients with T2DM (NCT00485758).

Keywords: HDL; LDL; hyperglycemia; lipid-modifying agents; triglycerides.

References

    1. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27(Suppl 1):S68–S71.
    1. Gotto AM., Jr High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J. 2002;144:S33–S42.
    1. Manzato E, Zambon A, Lapolla A, et al. Lipoprotein abnormalities in well-treated type II diabetic patients. Diabetes Care. 1993;16:469–475.
    1. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010;59:1153–1160.
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143–3421.
    1. Bays HE, Ballantyne C. What’s the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol. 2009;20:467–476.
    1. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med. 2000;160:1177–1184.
    1. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 2001;88:270–274.
    1. Morgan JM, Capuzzi DM, Baksh RI, et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol. 2003;91:1432–1436.
    1. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med. 2004;62:229–234.
    1. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med. 1994;154:1586–1595.
    1. Kamal-Bahl SJ, Burke TA, Watson DJ, Wentworth CE. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Curr Med Res Opin. 2008;24:1817–1821.
    1. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34:642–650.
    1. Mills E, Prousky J, Raskin G, et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] BMC Clin Pharmacol. 2003;3:4.
    1. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008;101:625–630.
    1. Sturino CF, O’Neill G, Lachance N, et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b] indol-3-Yl]-acetic acid (MK-0524) J Med Chem. 2007;50:794–806.
    1. Berge KG, Canner PL. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol. 1991;40(Suppl 1):S49–S51.
    1. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–1298.
    1. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
    1. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–1291.
    1. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
    1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–2581.
    1. MacLean A, McKenney JM, Scott R, et al. Efficacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitus. Br J Cardiol. 2011;18:37–45.
    1. Jellinger PS, Smith DA, Mehta AE, et al. American association of clinical endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18(Suppl 1):1–78.
    1. Guyton JR, Slee AE, Anderson T, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes) J Am Coll Cardiol. 2013;62:1580–1584.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner